Original ArticleLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Under a Creative Commons license
open access
Key words
carboplatin
veliparib
neoadjuvant chemotherapy
triple-negative breast cancer
phase III
Cited by (0)
© 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.